Richard Kincaid, Executive and Chief Financial Officer

Oct. 11 | 5:00pm | UBC Ballroom  

Tokyo, Japan 

(TSE: 4593) 

In-person Presentation 

Healios K.K. is a biotechnology venture leading the field of regenerative medicine and cell therapy. It was founded in 2011 and listed on the Tokyo Stock Exchange in 2015. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios K.K. is a pioneer in the development of regenerative medicines in Japan, and has established a proprietary, gene-edited universal donor induced pluripotent stem cell (iPSC) line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. The company’s lead iPSC-derived cell therapy candidate is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene editing. 



By using this website you agree to accept our Privacy Policy and Terms & Conditions